Commentary
Given the obesity epidemic, NAFLD and NASH have reached alarming levels globally. Recent data suggest that more than a quarter of the world population is affected by NAFLD, however, the disease prevalence is higher in certain patient population, i.e. among patients with type 2 diabetes.
The growing global burden of NAFLD has inspired research and expanded the understanding of pathophysiology, but also the burden it places on individuals, society and the healthcare systems worldwide. In this review, K. Kabarra et al. (Inova Fairfax Hospital, USA) focus on NAFLD/NASH and its clinical, economical, and patient related burdens.
